Previous 10 | Next 10 |
2023-09-05 11:16:44 ET Shares of Zai Lab (NASDAQ: ZLAB) were up more than 10% as of 11 a.m. on Tuesday. The Chinese biotech stock rose after the company announced positive phase 3 trial data regarding Tivdak as a front-line therapy to treat metastatic cervical cancer in patients...
2023-09-05 07:10:57 ET More on Genmab, Seagen, etc. Seagen Acquisition By Pfizer: A Strategic Power Move With Potential Windfalls For Investors Genmab Is Down To Attractive Levels Genmab A/S ( GMAB ) Q2 2023 Earnings Call Transcript Genmab: Epkinly's Appr...
Company Announcement Phase 3 innovaTV 301 confirmatory trial met its primary endpoint of improved overall survival (OS) at predetermined, independent interim analysis Trial results to be submitted for presentation at a future medical meeting Genmab and Seagen to engage i...
Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) announced today that the Phase 3 innovaTV 301 global trial in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy who received TIVDAK ® (tisotumab vedotin-tftv), compared w...
2023-08-31 05:42:17 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Despite polls showing most Americans are unhappy with the state of the economy, President Biden has defended his policies with claims he is improving the finances and living standards ...
2023-08-30 11:17:45 ET Summary Genmab's stock is down 15% since late 2022 highs but the company and its partners continue to execute well. The approval and launch of Epkinly for the treatment of DLBCL is a significant milestone for Genmab and Epkinly has the potential to become on...
2023-08-03 17:58:02 ET Genmab A/S (GMAB) Q2 2023 Earnings Conference Call August 3, 2023 12:00 PM ET Company Participants Jan van de Winkel - Co-Founder, President & CEO Anthony Pagano - EVP & CFO Judith Klimovsky - Chief Development Officer Anthony M...
2023-08-03 11:06:41 ET Genmab press release ( GMAB ): 1H GAAP EPS of DKK20.61. Revenue of DKK4.2B (+32.9% Y/Y). For further details see: Genmab GAAP EPS of DKK20.61, revenue of DKK4.2B
August 3 , 202 3 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2023 Highlights EPKINLY™ (epcoritamab- bysp ) was approved by the U.S. Food and Drug Administration (U.S. FDA) as the first bispecific antibody t...
2023-08-02 11:44:06 ET Genmab ( GMAB ) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open. The consensus EPS Estimate is $0.23 and the consensus Revenue Estimate is $600.62M Over the last 3 months, EPS estimates have seen 0 upward re...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 78.0% to $0.58749 on volume of 130,454,575 shares Ocean Power Technologies Inc. (OPTT) rose 29.6% to $0.2073 on volume of 51,927,154 shares Cosmos Health Inc. (COSM) rose 64.9% to $1.12 on volume of...
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcoritamab (TEPKINLY ® ...
2024-06-27 09:00:08 ET Kaveri Pohlman from BTIG issued a price target of $47.00 for GMAB on 2024-06-27 07:34:00. The adjusted price target was set to $47.00. At the time of the announcement, GMAB was trading at $25.67. The overall price target consensus is at $41.80 with...